Table 2.
Adverse events
| Grade 1/2 (n, %) |
P | Grade 3/4 (n, %) |
P | |||
|---|---|---|---|---|---|---|
| EGFR-TKI monotherapy (n = 19) | EGFR-TKI+ crizotinib (n = 9) | EGFR-TKI monotherapy (n = 19) | EGFR-TKI+ crizotinib (n = 9) | |||
| Rash | 6 (31.5) | 2 (22.2) | 0.103 | 0 (0) | 3 (33.3) | 0.026 |
| Diarrhea | 5 (26.3) | 1 (11.1) | 0.630 | 0 (0) | 1 (11.1) | 0.321 |
| Elevated aspartate aminotransferase | 4 (21) | 1 (11.1) | 1.000 | 1 (5.3) | 1 (11.1) | 1.000 |
| Nausea/vomiting | 2 (10.5) | 2 (22.2) | 0.574 | 0 (0) | 1 (11.1) | 0.321 |
| Neutropenia | 1 (5.7) | 0 (0) | 1.000 | 0 (0) | 0 (0) | — |
| Vision impairment | 0 (0) | 1 (11.1) | 0.321 | 0 (0) | 0 (0) | — |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.